Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with serious diseases, particularly cancer and other unmet medical needs. The company leverages its expertise in molecular biology and drug development to create targeted treatments that aim to improve patient outcomes. With a strong emphasis on research and clinical trials, Incyte strives to advance its pipeline of potential medications, which includes both its proprietary compounds and collaborations with other pharmaceutical partners. Through its commitment to scientific excellence and patient-centric approaches, Incyte aims to address significant healthcare challenges and enhance the quality of life for individuals suffering from complex conditions. Read More
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate.
Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA.
Excluding the $246 million one-time b
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on ...
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy...
Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid.
Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per...
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris.
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...
Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026.
Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder, to Incyte’s hematology portfolio.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
